MAIA Biotechnology, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
MAIA Biotechnology, Inc. (MAIA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of -1.40% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-03-23
- MAIA Biotechnology, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2025 was -1.40%.
- MAIA Biotechnology, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was -0.70%.
- MAIA Biotechnology, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was -2.20%.
- MAIA Biotechnology, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2022 was -1.20%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | -1.40% 10-K · filed 2026-03-23 | |
| 2024-12-31 | -0.70% 10-K · filed 2026-03-23 | -0.90% 10-K · filed 2025-03-21 |
| 2023-12-31 | -2.20% 10-K · filed 2025-03-21 | |
| 2022-12-31 | -1.20% 10-K · filed 2024-03-21 | |
| 2021-12-31 | -1.90% 10-K · filed 2023-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |